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Introduction
The t(8;21)(q22;q22) translocation occurs in 40% of
patients with acute myeloid leukemia (AML) of the FAB-M2
subtype, and constitutes 12% of all newly diagnosed cases of
AML.  This translocation leads to a fusion product of AML1
(also called RUNX1 or CBFβ) and ETO (also called MTG8).
Data have suggested that the translocation is an early event in
leukemogenesis.1 Furthermore, the t(8;21) translocation can
be found in neonatal Guthrie blood spots of infants that later
developed AML1-ETO leukemia, suggesting that the translo-
cation can precede development of AML by up to ten years.2,3
Several murine models have demonstrated that AML1-
ETO alone is not sufficient to induce leukemia.  Murine bone
marrow cells expressing tetracycline-inducible AML1-ETO
transgene did not develop leukemia:4 but developed myelo-
proliferative disorders.5 In contrast, 30-55% of AML1-ETO-
expressing mice treated with the DNA-alkylating mutagen
N-ethyl-N-nitrosourea (ENU) developed AML.6,7 These find-
ings strongly suggest that a secondary hit is necessary for the
development of t(8;21) AML.  
The protooncogene KIT is a receptor tyrosine kinase.
Activating mutations of KIT including those in either the
extracellular (exon 8) region or the protein kinase domains
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Translocation of chromosomes 8 and 21, t(8;21), resulting
in the AML1-ETO fusion gene, is associated with acute
myeloid leukemia. We searched for additional genomic
abnormalities in this acute myeloid leukemia subtype by
performing single nucleotide polymorphism genomic
arrays (SNP-chip) analysis on 48 newly diagnosed cases.
Thirty-two patients (67%) had a normal genome by SNP-
chip analysis (Group A), and 16 patients (33%) had one or
more genomic abnormalities including copy number
changes or copy number neutral loss of heterozygosity
(Group B). Two samples had copy number neutral loss of
heterozygosity on chromosome 6p including the PIM1
gene; and one of these cases had E135K mutation of Pim1.
Interestingly, 38% of Group B and only 13% of Group A
samples had a KIT-D816 mutation, suggesting that
genomic alterations are often associated with a KIT-D816
mutation. Importantly, prognostic analysis revealed that
overall survival and event-free survival of individuals in
Group B were significantly worse than those in Group A.
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(D816 mutation) are found in 2% and 11% of t(8;21)
AML samples, respectively.8,9 FLT3 is also a receptor
tyrosine kinase.  Two frequent activating mutations of
FLT3, FLT3-internal tandem duplication (ITD) and
FLT3-tyrosine kinase domain (TKD) mutation, are
detected in a range of 2-8% and 2-4% of samples of
t(8;21) AML, respectively.10,11 Mutation of NRAS at
either codon 12, 13 or 61 is found in 9% of t(8;21) AML
samples.10,11
High-density single nucleotide polymorphism
genomic arrays (SNP-chip) allow the detection of copy
number changes, as well as copy number neutral loss of
heterozygosity (CNN-LOH) in leukemia samples.12-18
In order to screen for secondary alteration(s) that
potentially could cause AML1-ETO transformed cells
to develop acute myeloid leukemia, we performed
SNP-chip analysis of 48 t(8;21) AML samples.  The use
of CNAG (copy number analysis for Affymetrix
GeneChips) program12 and an algorithm AsCNAR
(allele-specific copy number analysis using anonymous
references)13 allows identification of hidden abnormali-
ties and novel disease-related genomic regions in the
leukemia samples. Here, we found that genomic
changes detected by SNP-chip analysis are associated
with a poor overall and event-free survival in t(8;21)
AML.
Design and Methods
Patient samples, determination of mutant genes and
statistical analysis
Genomic DNA of 48 anonymized samples of t(8;21)
AML cells were obtained from Chang-Gung Memorial
Hospital, Chang-Gung University in Taiwan after obtain-
ing informed consent.  These samples had been frozen
over a span of 14 years (July 1990 to July 2004).  Sample
information is shown in the Online Supplementary Table
S1. The study has been approved by Cedars-Sinai
Medical Center (IRB number 4485).  
To detect an AML1-ETO fusion transcript, RT-PCR
was performed using specific primers as described previ-
ously.19 Mutation analysis of the KIT gene for the t(8;21)
AML samples was reported previously.20 Statistical analy-
sis is described in the Online Supplementary Design and
Methods section.
SNP-chip analysis
Genomic DNA isolated from t(8;21) AML cells was
subjected to GeneChip Human mapping microarray
(SNP-chip, Affymetrix, Santa Clara, CA, USA) as
described previously;12,13 ten samples (cases #47, #51,
#52, #54, #56, #57, #59, #60, #61 and #62) were exam-
ined with the 250 K array, and the other 38 samples
were analyzed with the 50 K array.  The allele-specific
copy numbers (AsCNs) were estimated using normal
genomic DNA from peripheral blood of normal volun-
teers as controls.13 The array does not contain Y-chro-
mosome probes; therefore, we summarize the SNP-
chip data without sex chromosomes. Size, position and
location of genes were identified with UCSC Genome
Browser (http://genome.ucsc.edu/). Copy number changes
previously described as copy number variants
(http://projects.tcag.ca/variation/) were excluded.
Fluorescence in situ hybridization (FISH) analysis
Interphase hybridizations were performed following
the manufacturer’s instructions and standard protocols.
Probes for the SNRPN gene, 15q telomere, 7p telomere
and 7q telomere were obtained from Cytocell
(Cambridge, United Kingdom); and probes for the MYC
gene as well as the centromere of chromosome 8 were
purchased from Abbott Molecular (Abbott Park, IL,
USA).  Fifty interphase cells were scored for each sam-
ple, with 20 cells scored in controls (bone marrow con-
trols with normal karyotypes). Signal patterns were nor-
mal for all controls with all probe sets. 
Analysis of the PIM1 gene
Six coding exons of the PIM1 gene were amplified
using specific primers from genomic DNA of cases #39
and #41.  After purification of the PCR products from
agarose gel, nucleotide sequences were determined.
Primer sequences will be provided upon request.  These
6 exons of other t(8;21) AML samples were examined by
single strand conformation polymorphism (SSCP) as
described in the Online Supplementary Design and Methods
section.
To determine the frequency of missense mutations of
the PIM1 gene within exon 4, this region of 34 t(8;21)
AML samples and 40 normal blood DNA samples were
amplified by PCR using specific primer (5’-TCC TGG
AGA GGC CCG AGC-3’ and 5’-TTG AGG TCG ATA
AGG ATG-3’).  The PCR product (178 bp) was treated
with a restriction enzyme Hpy188III for 1h.  PCR prod-
ucts from wild-type allele are not digested but mutated
allele are digested by the restriction enzyme.
Results and Discussion
SNP-chip analysis of 48 t(8;21) acute myeloid
leukemia samples
SNP-chip analysis of 48 t(8;21) acute myeloid
leukemia (AML) samples revealed several genomic copy
number changes, as well as copy number neutral loss of
heterozygosity (CNN-LOH).  As shown in Table 1 and
Online Supplementary Figure S1, 32 patients (67%) had a
normal genome by SNP-chip analysis (Group A, mean
age is 23, range 2-74). In contrast, 16 patients (33%) had
one or more genomic abnormalities (Group B, mean age
is 31, range 4-61). Thus, these copy number changes
probably harbor dysregulated leukemia-associated
genes in t(8;21) AML. Cytogenetics showed that case
#33 had trisomy 4 in 2 out of 15 cells (13%), and case
#34 had monosomy 18 in 6 out of 24 cells (25%) (Online
Supplementary Table S1). These minor clones were not
detected by SNP-chip analysis. Case #40 had tetraploidy
in 23 out of 25 cells; 2-fold gene-dosage in all chromo-
somes was masked and detected as normal gene-dosage. 
Next, we compared SNP-chip results and gene muta-
tions. Ten out of 48 samples (18%) had a KIT-D816
mutation. Interestingly, 6 (case #7, #14, #26, #37, #40,
and #52) of the 10 samples were found in Group B,
demonstrating that KIT-D816 mutation is significantly
associated with Group B (p<0.05, χ2 test). This result
suggests that copy number changes are often involved
in cases with a KIT-D816 mutation in t(8;21) AML.
Recurrent copy number changes in t(8;21) acute
myeloid leukemia samples
Two cases (#34 and #37) had a duplication on chro-
mosome 8 from 8q22.1 to q-terminal including the
MYC gene; and 2 cases (#13 and #28) had a
trisomy/duplication on chromosome 15 with common
duplicated region at 15q21.1-15q-terminal (53.7 Mb).
Four cases (#14, #34, #43 and #60) had a deletion/mono-
somy on chromosome 7 with a common deleted region
at 7q35 - 7q36.1 (2.1 Mb) including the CUL1 and EZH2
genes; and 2 cases (#17 and #34) had a deletion on chro-
mosome 9 with the common deleted region at 9q13 -
9q36.1 (16.2 Mb). Interestingly, a frequent large duplica-
tion was found on chromosome 4. Two cases had tri-
somy 4, and one case had a large region of duplication
on chromosome 4 from 4p16.1 to q28.3 (131.1 Mb). All
of these amplifications covered the region of the KIT
gene; and 3 of these cases (#26, #37 and #39) had a KIT
mutation of either D816Y, D816V or D820G.
Amplification of chromosome 4 linked to KIT muta-
tions has previously been described in systemic masto-
cytosis.21 Thus, the probable increased expression of the
mutated form of KIT by trisomy 4 or duplication in the
region of the gene should give the clone a proliferative
advantage.
Validation of copy number change by fluorescence in
situ hybridization (FISH) 
To validate some of these copy number changes, we
used an interphase FISH approach. Case #34 had a
duplication of 8q22.1-8q-terminal (46.6 Mb) including
the MYC gene and a deletion of 7q31.2-7q-terminal
(42.0 Mb). The 8q duplication was confirmed using
FISH probes for MYC and the centromere of chromo-
some 8 (Online Supplementary Figure S2A). In the same
case, deletion of chromosome 7q (q31.2 to q-terminal)
was confirmed using FISH probes for 7p telomere and
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Table 1. Chromosomal regions with copy number changes and copy number neutral loss of heterozygosity in t(8; 21) acute myeloid leukemia
samples.
Physical localization
Case # Status Location Proximal Distal Size (Mb) Genes
6 Dup 8q24.23 137,858,383 137,892,295 0.03 No known genes
7 Dup 18q21.32 56,209,691 56,315,439 0.1 No known genes
CNN-LOH 11pter-p12 1,938,894 42,449,197 40.5 >10 genes including CDKN1C, HRAS, and WT1
13 Tri Trisomy 15 − − − >10 genes
14 Del 7q35-q36.1 146,128,574 148,288,861 2.1 CNTNAP2, CUL1, EZH2, 
PDIA4, ZNF425, ZNF298
17 Del 9q13-q36.1 68,275,512 84,477,002 16.2 >10 genes
26 Tri Trisomy 4 − − − >10 genes including KIT
Del 13q21.1 54,339,313 54,457,753 0.1 no known genes
28 Dup 15q21.1-qter. 46,526,374 100,182,183 53.7 >10 genes
Del 16pter -p13.2 1,543,577 7,010,644 5.5 >10 genes
34 Del 7q31.2-qter. 116,548,736 158,554,645 42 >10 genes
Dup 8q22.1-qter. 97,255,867 143,902,698 46.6 >10 genes including MYC
Del 9q33.1 116,515,445 117,926,188 1.4 TNFSF15, TNFSF8, TNC, 
DEC1, CTS9, EST-YD1 
Del 9q13-q31.3 68,275,512 109,232,711 41 > 10 genes
37 Dup 4p16.1-q28.3 7,902,265 139,029,890 131.1 >10 genes including KIT
Dup 8q22.1-qter. 96,550,847 143,902,698 47.4 >10 genes including MYC
39 Tri Trisomy 4 − − − >10 genes including KIT
Dup 14q11.2-q13.1 19,285,288 33,978,199 14.7 >10 genes
CNN-LOH 6pter-p12.3 150,610 46,902,007 46.8 >10 genes including PIM1 and CDKN1A
40 Mono Monosomy 11 − − − >10 genes
41 CNN-LOH 6p-ter. - 6p21.1 150,610 44,873,513 44.7 >10 genes  including PIM1 and CDKN1A
43 Mono Monosomy 7 − − − >10 genes
52 Dup 5q14.1 77034347 77551493 0.5 TBCA, AP3B1
59 CNN-LOH 11q13.2 - q-ter. 67259252 134439182 67.2 >10 genes
Del 16q21 57560512 58960978 1.4 no known genes
60 Dup 1q41 - q-ter. 211518337 245353397 33.8 >10 genes
Del 7q31.32 121860398 122756128 0.9 CADPS2, RNF133, RNF148, 
AK058116, TAS2R16, SLC13A1 
Del 7q31.33 - q-ter. 123544140 158605053 35.1 >10 genes
Physical localization and size (Mb) are obtained from UCSC Genome Browser. Copy number changes previously described as copy number variant were excluded.CNN-
LOH; copy number neutral loss of heterozygosity,Del; deletion,Dup; duplication,Tri; trisomy,Mono; monosomy, ter.; terminal.
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7q telomere (Online Supplementary Figure S2B). Case #28
had a large duplication of chromosome 15 (53.7 Mb).
The duplication was confirmed using FISH probes for
SNRPN and 15q telomere (Online Supplementary Figure
S2C). These results suggest that abnormalities detected
by SNP-chip analysis reflected real alterations in AML
cells.
Chromosomal regions and candidate genes in genom-
ic areas with copy number neutral loss of
heterozygosity (CNN-LOH)
Four cases (8%) had CNN-LOH (Table 1 and Online
Supplementary Figure S1). Case #7 has CNN-LOH at 11p-
terminal-11p12 (40.5 Mb) which included the CDKN1C,
HRAS, WT1 and LMO2 genes. Case #39 and #41 have
CNN-LOH at 6p-terminal - 6p12.3 (46.8 Mb) and at 6p-
terminal - 6p21.1 (44.7 Mb), respectively; and the region
contained the PIM1 and CDKN1A genes (Table 1 and
Online Supplementary Figure S3). Case #59 had CNN-
LOH at 11q13.2-q-terminal (67.2 Mb). Raghavan et al.15
showed that approximately 20% AML samples had
CNN-LOH, and Gondek et al.16 found that 20% of MDS,
23% of MDS-derived AML, and 35% of MDS/MPD
patients had CNN-LOH.  In additional studies, we found
that 32% of normal karyotype AML samples and 15%
of t(15;17) APL samples had CNN-LOH.17,18 CNN-LOH
in t(8;21) AML is less frequent than many other types of
leukemia.
Acquired mutation of the PIM1 gene
The protooncogene PIM1, which encodes the serine-
threonine protein kinase, is located on chromosome 6p,
and 2 cases had CNN-LOH in the region. All exons of
the PIM1 gene for these 2 cases were examined for
mutations. As shown in Figure 1A, case #39 had a nucle-
ic acid change of G to A at exon 4 of the PIM1 gene lead-
ing to an amino acid change of glutamic acid (E) to lysine
(K) at codon 135 (E135K). The amino acid change
occurred between the ATP-binding site and serine-thre-
onine kinase domain. The wild-type amino acid is con-
served between human, rat, mouse and xenopus.
Importantly, the complete remission sample of the same
individual showed the wild-type sequence, demonstrat-
ing that the nucleic acid change was a disease-specific
acquired alteration.
The missense mutation in the PIM1 gene change pro-
duces the recognition site of a restriction enzyme,
Hpy188III. A total of 34 t(8;21) AML samples and 40
normal blood DNA samples were examined for this
mutation by Hpy188III digestion. The PCR product (178
bp) encompassing the mutation was only digested in
case #39 (Figure 1B), but not the DNA from the other
AML samples or normal blood DNA (data not shown),
suggesting it is infrequent in the AML subtype. We also
examined all exons of the PIM1 gene by SSCP using 34
t(8;21) AML samples, but no shifted bands were detect-
ed other than exon 4 of case #39. The PIM1 E135K
mutant was also detected in B-cell diffuse large-cell lym-
phoma;22 and another mutant (E135Q) was discovered in
primary diffuse large B-cell lymphomas.23 It remains to
be clarified whether the E135K mutant is activated con-
stitutively.
Prognostic significance of genomic change
Overall survival of t(8;21) AML patients of Group A
(no genomic abnormality observed by SNP-chip) was
significantly better than individuals in Group B (genom-
ic abnormality observed by SNP-chip) (hazard
ratio=2.992 [95% confidence interval, 1.247-7.179],
p=0.01) (Figure 2). The event-free survival of individuals
of Group A was also significantly better than those in
Group B (hazard ratio=2.360 [95% confidence interval,
1.037-5.372], p=0.0347). We also compared the progno-
sis of individuals with the KIT-D816 mutation (6 cases)
to those without the alteration (10 cases) in Group B, but
found no significant difference (data not shown).  These
results strongly suggest that genomic changes in t(8;21)
AML are associated with a poor overall and event-free
survival.
Figure 1. Acquired mutation of the PIM1 gene in case #39. (A)
Exon 4 of the PIM1 gene in case #39 had a missense mutation in
the sample at diagnosis but not at remission (top panel). The
mutation leads to the amino acid change of glutamic acid (E) to
lysine (K) at amino acid 135 (E135K) of PIM1 protein.  This mutat-
ed amino acid is located between the ATP binding domain and
serine-threonine kinase domain of the protein  (middle panel).
The wild-type amino acid (E) is highly conserved among human,
rat, mouse and xenopus (bottom). Note, *identical amino acid.  (B)
The mutated DNA sequence produced a Hpy188III restriction
enzyme recognition sequence. The region was amplified by PCR,
digested with Hpy188III, and subjected to agarose gel elec-
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A recent study showed that a KIT-D816V mutation is
associated with a poor prognosis in t(8;21) AML
patients.9 Also, secondary cytogenetic abnormalities
including trisomy of chromosome 8 and 4,
deletion/duplication of chromosome 7, as well as dele-
tion of chromosome X and Y in t(8;21) AML have previ-
ously been reported to be associated with a poor progno-
sis.24 Taken together, these findings indicate that genom-
ic alterations and KIT-D816 mutation confer a poor prog-
nosis in t(8;21) AML patients.  Further studies in a larger
cohort of patients will begin to stratify prognostically the
patients in relation to the genomic changes; and new
therapeutic targets should be discovered.
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Figure 2. Comparison of overall survival and event-free survival of t(8;21) acute myeloid leukemia patients either with or without genom-
ic changes. Overall survival (left) and event-free survival (right) were compared between Groups A and B. Black and grey lines indicate
Group A (no genomic abnormality by SNP-chip) and Group B (genomic abnormality by SNP-chip), respectively. 
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